{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:47:50Z","timestamp":1777456070536,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"4","funder":[{"name":"Japan Ministry of Health, Labour, and Welfare","award":["JPMH20FC1033"],"award-info":[{"award-number":["JPMH20FC1033"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,8,10]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compared with cytotoxic chemotherapy, the efficacy and safety of immune checkpoint inhibitors (ICIs) for patients with interstitial lung disease and non-small cell lung cancer (ILD-NSCLC) are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of patients in a Japanese nationwide insurance claims database with ILD-NSCLC who received ICIs (ICI group, n=1748) and those who received only chemotherapy without ICIs (chemotherapy group, n=6362) were extracted. Landmark analyses were performed to compare overall survival (OS) between the two groups. Propensity-score matching was performed to compare 753 patients who received ICI as the first-line treatment (first-ICI group) and 753 from the chemotherapy group with matched backgrounds (matched chemotherapy group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ICI group had a significantly longer median OS of 19.7 months than the chemotherapy group (9.9 months; HR 0.51, 95% CI 0.47 to 0.54, p&lt;0.001). In landmark analyses at 3, 6, 9 and 12 months, the ICI group had a significantly longer OS than the chemotherapy group (all p&lt;0.001). The incidence of drug-induced ILD (DIILD) was significantly higher in the ICI group than in the chemotherapy group (p&lt;0.001). In the ICI group, there was no significant difference in OS between patients with and without DIILD (p=0.784). A propensity score-matched analysis indicated that the first-ICI group had a significantly longer OS than the matched chemotherapy group (p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with ILD-NSCLC, ICIs were associated with significantly longer OS compared with cytotoxic chemotherapy, despite the increased risk of DIILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223430","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:21:04Z","timestamp":1760548864000},"page":"328-335","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-4070","authenticated-orcid":false,"given":"Masato","family":"Karayama","sequence":"first","affiliation":[{"name":"Department of Chemotherapy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3550-1182","authenticated-orcid":false,"given":"Koichi","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-1543","authenticated-orcid":false,"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-9791","authenticated-orcid":false,"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-1781","authenticated-orcid":false,"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-4264","authenticated-orcid":false,"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026042806000677000_81.4.328.1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201807-481OC"},{"key":"2026042806000677000_81.4.328.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202360","article-title":"Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis","volume":"13","author":"JafariNezhad","year":"2018","journal-title":"PLoS One"},{"key":"2026042806000677000_81.4.328.3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12890-019-0905-8","article-title":"Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"19","author":"Yoo","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026042806000677000_81.4.328.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01547.x"},{"key":"2026042806000677000_81.4.328.5","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.75"},{"key":"2026042806000677000_81.4.328.6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.resinv.2018.03.002","article-title":"Anticancer drug treatment for advanced lung cancer with interstitial lung disease","volume":"56","author":"Otsubo","year":"2018","journal-title":"Respir Investig"},{"key":"2026042806000677000_81.4.328.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2019.06.001"},{"key":"2026042806000677000_81.4.328.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"2026042806000677000_81.4.328.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2026042806000677000_81.4.328.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026042806000677000_81.4.328.11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x"},{"key":"2026042806000677000_81.4.328.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026042806000677000_81.4.328.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv182"},{"key":"2026042806000677000_81.4.328.14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004759"},{"key":"2026042806000677000_81.4.328.15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s42399-020-00259-3","article-title":"Clinical Outcomes of Anti-programmed Death-1 Antibody\u2013Related Pneumonitis in Patients with Non-Small Cell Lung Cancer","volume":"2","author":"Koyauchi","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"2026042806000677000_81.4.328.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"2026042806000677000_81.4.328.17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"2026042806000677000_81.4.328.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"2026042806000677000_81.4.328.19","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200409","article-title":"Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers","volume":"93","author":"Nobashi","year":"2020","journal-title":"Br J Radiol"},{"key":"2026042806000677000_81.4.328.20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1759-7714.13736","article-title":"Outcome and risk factor of immune\u2010related adverse events and pneumonitis in patients with advanced or postoperative recurrent non\u2010small cell lung cancer treated with immune checkpoint inhibitors","volume":"12","author":"Isono","year":"2021","journal-title":"Thorac Cancer"},{"key":"2026042806000677000_81.4.328.21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr-22-72","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer","volume":"11","author":"Chao","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"2026042806000677000_81.4.328.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026042806000677000_81.4.328.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042806000677000_81.4.328.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2026042806000677000_81.4.328.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"2026042806000677000_81.4.328.26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"2026042806000677000_81.4.328.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.12.656"},{"key":"2026042806000677000_81.4.328.28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.37737\/ace.2.1_13","article-title":"A review of studies using the Japanese National Database of Health Insurance Claims and Specific Health Checkups","volume":"2","author":"Hirose","year":"2020","journal-title":"ACE"},{"key":"2026042806000677000_81.4.328.29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","article-title":"Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease","volume":"155","author":"Tasaka","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"2026042806000677000_81.4.328.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168465","article-title":"Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"11","author":"Fujimoto","year":"2016","journal-title":"PLoS One"},{"key":"2026042806000677000_81.4.328.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.016"},{"key":"2026042806000677000_81.4.328.32","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318216ee6b"},{"key":"2026042806000677000_81.4.328.33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","article-title":"Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study","volume":"15","author":"Johkoh","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"2026042806000677000_81.4.328.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"2026042806000677000_81.4.328.35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2016.03.017","article-title":"Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer","volume":"96","author":"Enomoto","year":"2016","journal-title":"Lung Cancer (Auckl)"},{"key":"2026042806000677000_81.4.328.36","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41598-022-05138-6","article-title":"New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Sakamoto","year":"2022","journal-title":"Sci Rep"},{"key":"2026042806000677000_81.4.328.37","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2020.04.002"},{"key":"2026042806000677000_81.4.328.38","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026042806000677000_81.4.328.39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur Respir J"},{"key":"2026042806000677000_81.4.328.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:00:56Z","timestamp":1777381256000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/thorax-2025-223430"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223430","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}